Sex and Autoimmunity: Proposed Mechanisms of Disease Onset and Severity
Overview
Authors
Affiliations
Chronic autoimmune diseases affect 5-10% of the population worldwide and are largely predominant in women. Sex hormone changes have been widely investigated based on changes in the clinical phenotypes observed during pregnancy and menopause. It is known that females with autoimmune diseases manifest a higher rate of circulating leukocytes with a single X chromosome, and there have been several reports on the role of X chromosome gene dosage through inactivation or duplication in autoimmunity. However, it is also important not to overlook men with autoimmune diseases, who might manifest a more frequent loss of the Y chromosome in circulating leukocytes. Areas covered: In the present review, we will discuss the current evidence supporting the mechanisms of female predominance in rheumatic diseases, by discussing the role of reproductive history, sex hormones and abnormalities related to them, clinical differences between male and female patients, and epigenetic changes that have been evaluated through twin studies on genetic and environmental changes in rheumatic patients. Expert opinion: The influence of sex hormones and chromosomes on the function of the innate and adaptive immune systems needs to be clarified, to better understand the risk of autoimmune diseases, early diagnostic tools, and therapeutic response.
Impact of endocrine disruptors on peripheral blood mononuclear cells in vitro: role of gender.
Maddalon A, Cari L, Iulini M, Alhosseini M, Galbiati V, Marinovich M Arch Toxicol. 2023; 97(12):3129-3150.
PMID: 37676302 PMC: 10567873. DOI: 10.1007/s00204-023-03592-3.
Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?.
Cortese R, Mariotto S, Mancinelli C, Tortorella C Front Neurol. 2023; 13:1048502.
PMID: 36601293 PMC: 9806181. DOI: 10.3389/fneur.2022.1048502.
EEG-Delta brushes in DPPX encephalitis - Welcome to the club.
Heuer C, Disse L, Ledergerber D, Jelcic I, Imbach L Clin Neurophysiol Pract. 2022; 8:12-15.
PMID: 36583162 PMC: 9792293. DOI: 10.1016/j.cnp.2022.11.003.
Wu H, Zeng L, Ou J, Wang T, Chen Y, Nandakumar K Front Immunol. 2022; 13:818173.
PMID: 35663991 PMC: 9160234. DOI: 10.3389/fimmu.2022.818173.
Gender-affirming hormone therapy induces specific DNA methylation changes in blood.
Shepherd R, Bretherton I, Pang K, Mansell T, Czajko A, Kim B Clin Epigenetics. 2022; 14(1):24.
PMID: 35177097 PMC: 8851870. DOI: 10.1186/s13148-022-01236-4.